Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trial.

Masahiko ShimuraHideyasu OhTetsuo UedaShigehiko KitanoYoshinori MitamuraJunko SatoKeisuke IwasakiAkito Hirakatanull null

Published in: Japanese journal of ophthalmology (2024)

Faricimab up to Q16W offered durable vision gains and anatomic improvements up to 2 years in patients with DME in the YOSEMITE Japan subgroup. Outcomes were generally consistent with the pooled YOSEMITE/RHINE cohort.

Keyphrases

phase iii
open label
clinical trial
phase ii
study protocol
double blind
placebo controlled
randomized controlled trial
metabolic syndrome
gestational age
type diabetes
adipose tissue
glycemic control